The drug has been through a series of small-scale studies to determine whether or not it can or should be used to help those suffering with PTSD. Due to the success of these studies, the Food and Drug Administration (FDA) approved MDMA to enter a Phase 3 clinical trial.
This approval is significant because a Phase 3 clinical trial is the final testing stage before a drug can be considered for approval as a formal prescription drug.
In the New York Times article, Dr. Charles R. Marmar of New York University’s Langone School of Medicine described himself as, “cautious but hopeful.”
Marmar is the head of psychiatry at NYU. He is a leading PTSD researcher but did not partake in the study on MDMA.
Study results have been promising, with participants experiencing improvements in their PTSD symptoms and overall alleviation of their condition after MDMA therapy.
“If they can keep getting these good results, it will be of great use,” Marmar said.
There are, of course, concerns about the drug since it is well-known for people abusing it.
The FDA was unable to comment to the Times because the drug is still being studied and developed.